MedPath

Blood-stage Malaria Vaccine Candidate RH5.1/Matrix-M Trial in Tanzania

a year ago1 min read
A recent phase 1b trial has been conducted to evaluate the safety and immunogenicity of the blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children. This open-label, non-randomised, first-in-human, single-centre trial represents a crucial advancement in the development of a vaccine against malaria, a disease that continues to pose a significant health burden in many parts of the world, particularly in sub-Saharan Africa. The trial's findings are expected to contribute valuable insights into the potential of RH5.1/Matrix-M as a viable vaccine candidate for malaria prevention.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.